A panel of FDA advisors has recommended reclassifying four unproven peptides—BPC-157, KPV, TB-500, and MOTs-C—to allow compounding pharmacies to legally dispense them.The decision, which passed 8-6 with one abstention, comes amid growing popularity of peptides among influencers and wellness advocates.

Despite warnings from FDA scientists about insufficient evidence for safety and efficacy, proponents argue legal access would provide safer alternatives to the unregulated gray market.Critics, including medical experts and advocacy groups, warn that FDA approval could legitimize unproven treatments and perpetuate a black market.The debate highlights tensions between patient access, regulatory oversight, and the risks of untested therapies.Peptides, marketed for everything from injury recovery to skin rejuvenation, face scrutiny over their lack of scientific backing.The FDA’s final decision is expected in months, with implications for both public health and the pharmaceutical industry.